

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

NCT06483555

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	UNC Lineberger Comprehensive Cancer Center
Enrollment	104 participants

Plain Language Summary

This study is testing a three-drug chemotherapy combination — gemcitabine, erlotinib, and nab-paclitaxel — specifically in patients with "basal-like" pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive subtype of pancreatic cancer identified by genetic profiling. The goal is to see if this combination works better for this specific subtype.

****You may be eligible if...****

- You are 18 or older
- You have been diagnosed with basal-like pancreatic ductal adenocarcinoma (confirmed by molecular testing)
- Your ECOG performance status is 0 or 1 (you are fully active or have minor limitations)
- You have consented to provide a biopsy if archival tissue is not available
- Your disease is measurable on scans

****You may NOT be eligible if...****

- Your disease is not measurable by standard imaging criteria
- You have severe organ impairment that would make chemotherapy unsafe
- You have an active unrelated cancer that could interfere with this study

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (6)

- Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information. Subjects is willing and able to comply with study procedures based on the judgment of the investigator.
- Age e 18 years at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 Histological or cytological evidence/confirmation of unresectable, borderline resectable, or metastatic (basal-like and classical) pancreatic adenocarcinoma.
- The subject must consent to a mandatory pre-study biopsy if archival tissue is not available or sufficient.
- Subjects may have received prior standard-of-care (SOC) neoadjuvant therapy and may have received up to two cycles of first-line FOLFIRINOX or NALIRIFOX.

... and 1 more (see full listing online)

Exclusion (3)

- Disease is not measurable according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1
- Not having histological or cytological evidence/confirmation of metastatic pancreatic adenocarcinoma.
- Treatment with any investigational drug or prior cancer treatment within 28 days prior to study treatment

Locations (1 total)

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
<https://clinicaltrials.gov/study/NCT06483555>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).